{"id":55884,"date":"2026-01-30T12:45:56","date_gmt":"2026-01-30T04:45:56","guid":{"rendered":"https:\/\/flcube.com\/?p=55884"},"modified":"2026-01-30T12:45:56","modified_gmt":"2026-01-30T04:45:56","slug":"hengrui-cancer-combo-gets-nmpa-nod-for-liver-cancer-trials","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=55884","title":{"rendered":"Hengrui Cancer Combo Gets NMPA Nod for Liver Cancer Trials"},"content":{"rendered":"\n<p><strong>Jiangsu Hengrui Pharmaceuticals Co., Ltd<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/600276:SHA\">SHA:\u202f600276<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/1276:HKG\">HKG:\u202f1276<\/a>) announced that a <strong>supplementary Biologics License Application (sBLA)<\/strong> for its PD\u20111 monoclonal antibody <strong>camrelizumab<\/strong> has been accepted for review by the <strong>National Medical Products Administration (NMPA)<\/strong>. The company seeks approval for camrelizumab combined with <strong>apatinib<\/strong> and <strong>transarterial chemoembolization (TACE)<\/strong> for the treatment of <strong>unresectable hepatocellular carcinoma (HCC)<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone-amp-combination-strategy\">Regulatory Milestone &amp; Combination Strategy<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Jiangsu Hengrui Medicine Co., Ltd (600276.SH)<\/td><\/tr><tr><td><strong>Drug<\/strong><\/td><td>Camrelizumab (PD\u20111 mAb)<\/td><\/tr><tr><td><strong>Combination<\/strong><\/td><td>Camrelizumab + apatinib + TACE<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Unresectable hepatocellular carcinoma (HCC)<\/td><\/tr><tr><td><strong>Application Type<\/strong><\/td><td>Supplementary Biologics License Application (sBLA)<\/td><\/tr><tr><td><strong>Status<\/strong><\/td><td>Accepted for review by NMPA<\/td><\/tr><tr><td><strong>Camrelizumab Launch<\/strong><\/td><td>First approved in China May\u202f2019<\/td><\/tr><tr><td><strong>Prior Approvals<\/strong><\/td><td>Liver cancer, lung cancer, ESCC, NPC, lymphoma<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism-of-action\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Camrelizumab:<\/strong> PD\u20111 checkpoint inhibitor that restores T\u2011cell mediated anti\u2011tumor immunity; Hengrui\u2019s flagship immuno\u2011oncology asset with <strong>5+ approved indications<\/strong> in China<\/li>\n\n\n\n<li><strong>Apatinib:<\/strong> Selective VEGFR\u20112 tyrosine kinase inhibitor (TKI) that blocks tumor angiogenesis; first approved in <strong>2014<\/strong> for advanced gastric cancer, now with <strong>4 total indications<\/strong><\/li>\n\n\n\n<li><strong>TACE:<\/strong> Standard interventional radiology procedure delivering localized chemotherapy to liver tumors<\/li>\n\n\n\n<li><strong>Synergistic Rationale:<\/strong> Triple combination aims to maximize anti\u2011tumor efficacy through <strong>immune activation (PD\u20111), anti\u2011angiogenesis (VEGFR\u20112), and locoregional cytotoxicity (TACE)<\/strong> in HCC, a highly vascular and immunosuppressive tumor microenvironment<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-commercial-outlook\">Market Impact &amp; Commercial Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>China HCC Burden:<\/strong> <strong>~400,000 new HCC cases<\/strong> annually; unresectable disease represents <strong>70%<\/strong> of diagnoses with <strong>5\u2011year survival &lt;15%<\/strong><\/li>\n\n\n\n<li><strong>Standard of Care:<\/strong> Limited to sorafenib\/lenvatinib and PD\u20111\/VEGF combos; no approved triplet regimens exist<\/li>\n\n\n\n<li><strong>Competitive Landscape:<\/strong> Competes with <strong>BeiGene\u2019s tislelizumab + lenvatinib<\/strong> and <strong>Innovent\u2019s sintilimab + bevacizumab biosimilar<\/strong>; Hengrui\u2019s TACE integration offers differentiation<\/li>\n\n\n\n<li><strong>Revenue Potential:<\/strong> Analysts project <strong>\u00a51.5\u20132.0\u202fbillion<\/strong> (US$210\u2013280\u202fmillion) peak annual sales potential if approved, leveraging Hengrui\u2019s established oncology sales force<\/li>\n\n\n\n<li><strong>Strategic Value:<\/strong> sBLA acceptance demonstrates regulatory confidence; positions Hengrui as leader in HCC combination therapy innovation<\/li>\n\n\n\n<li><strong>Next Steps:<\/strong> NMPA priority review possible given unmet need; approval anticipated <strong>H2\u202f2027<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding regulatory review timelines, clinical outcomes, and commercial expectations for the camrelizumab combination. Actual results may differ due to NMPA review processes, competitive dynamics, and market adoption rates.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA:\u202f600276, HKG:\u202f1276) announced that a supplementary Biologics License Application (sBLA)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":55886,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,2586,4228,38,4551],"class_list":["post-55884","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-cancer","tag-hengrui-pharmaceuticals","tag-hkg-1276","tag-market-approval-filings","tag-sha-600276-2"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Hengrui Cancer Combo Gets NMPA Nod for Liver Cancer Trials - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA:\u202f600276, HKG:\u202f1276) announced that a supplementary Biologics License Application (sBLA) for its PD\u20111 monoclonal antibody camrelizumab has been accepted for review by the National Medical Products Administration (NMPA). The company seeks approval for camrelizumab combined with apatinib and transarterial chemoembolization (TACE) for the treatment of unresectable hepatocellular carcinoma (HCC).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=55884\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hengrui Cancer Combo Gets NMPA Nod for Liver Cancer Trials\" \/>\n<meta property=\"og:description\" content=\"Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA:\u202f600276, HKG:\u202f1276) announced that a supplementary Biologics License Application (sBLA) for its PD\u20111 monoclonal antibody camrelizumab has been accepted for review by the National Medical Products Administration (NMPA). The company seeks approval for camrelizumab combined with apatinib and transarterial chemoembolization (TACE) for the treatment of unresectable hepatocellular carcinoma (HCC).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=55884\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-30T04:45:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/3005.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55884#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55884\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Hengrui Cancer Combo Gets NMPA Nod for Liver Cancer Trials\",\"datePublished\":\"2026-01-30T04:45:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55884\"},\"wordCount\":358,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55884#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/3005.webp\",\"keywords\":[\"Cancer\",\"Hengrui Pharmaceuticals\",\"HKG: 1276\",\"Market approval filings\",\"SHA:\u202f600276\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55884#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55884\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=55884\",\"name\":\"Hengrui Cancer Combo Gets NMPA Nod for Liver Cancer Trials - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55884#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55884#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/3005.webp\",\"datePublished\":\"2026-01-30T04:45:56+00:00\",\"description\":\"Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA:\u202f600276, HKG:\u202f1276) announced that a supplementary Biologics License Application (sBLA) for its PD\u20111 monoclonal antibody camrelizumab has been accepted for review by the National Medical Products Administration (NMPA). The company seeks approval for camrelizumab combined with apatinib and transarterial chemoembolization (TACE) for the treatment of unresectable hepatocellular carcinoma (HCC).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55884#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55884\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55884#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/3005.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/3005.webp\",\"width\":1080,\"height\":608,\"caption\":\"Hengrui Cancer Combo Gets NMPA Nod for Liver Cancer Trials\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55884#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hengrui Cancer Combo Gets NMPA Nod for Liver Cancer Trials\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Hengrui Cancer Combo Gets NMPA Nod for Liver Cancer Trials - Insight, China&#039;s Pharmaceutical Industry","description":"Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA:\u202f600276, HKG:\u202f1276) announced that a supplementary Biologics License Application (sBLA) for its PD\u20111 monoclonal antibody camrelizumab has been accepted for review by the National Medical Products Administration (NMPA). The company seeks approval for camrelizumab combined with apatinib and transarterial chemoembolization (TACE) for the treatment of unresectable hepatocellular carcinoma (HCC).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=55884","og_locale":"en_US","og_type":"article","og_title":"Hengrui Cancer Combo Gets NMPA Nod for Liver Cancer Trials","og_description":"Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA:\u202f600276, HKG:\u202f1276) announced that a supplementary Biologics License Application (sBLA) for its PD\u20111 monoclonal antibody camrelizumab has been accepted for review by the National Medical Products Administration (NMPA). The company seeks approval for camrelizumab combined with apatinib and transarterial chemoembolization (TACE) for the treatment of unresectable hepatocellular carcinoma (HCC).","og_url":"https:\/\/flcube.com\/?p=55884","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-30T04:45:56+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/3005.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=55884#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=55884"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Hengrui Cancer Combo Gets NMPA Nod for Liver Cancer Trials","datePublished":"2026-01-30T04:45:56+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=55884"},"wordCount":358,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=55884#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/3005.webp","keywords":["Cancer","Hengrui Pharmaceuticals","HKG: 1276","Market approval filings","SHA:\u202f600276"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=55884#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=55884","url":"https:\/\/flcube.com\/?p=55884","name":"Hengrui Cancer Combo Gets NMPA Nod for Liver Cancer Trials - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=55884#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=55884#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/3005.webp","datePublished":"2026-01-30T04:45:56+00:00","description":"Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA:\u202f600276, HKG:\u202f1276) announced that a supplementary Biologics License Application (sBLA) for its PD\u20111 monoclonal antibody camrelizumab has been accepted for review by the National Medical Products Administration (NMPA). The company seeks approval for camrelizumab combined with apatinib and transarterial chemoembolization (TACE) for the treatment of unresectable hepatocellular carcinoma (HCC).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=55884#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=55884"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=55884#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/3005.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/3005.webp","width":1080,"height":608,"caption":"Hengrui Cancer Combo Gets NMPA Nod for Liver Cancer Trials"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=55884#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Hengrui Cancer Combo Gets NMPA Nod for Liver Cancer Trials"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/3005.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55884","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=55884"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55884\/revisions"}],"predecessor-version":[{"id":55887,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55884\/revisions\/55887"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/55886"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=55884"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=55884"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=55884"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}